73 yr old 75 kilos Type 2 DM A1c of 11.7 with fasting glucose of 242
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
I now have enough rich content to provide a comprehensive, evidence-based answer. Here's a full clinical assessment and management plan:
Clinical Assessment: 73-year-old, 75 kg, Type 2 DM — A1c 11.7%, Fasting Glucose 242 mg/dL
Interpretation
This patient has severely uncontrolled T2DM. An A1c of 11.7% corresponds to an estimated average glucose of ~286 mg/dL, and the fasting glucose of 242 mg/dL confirms persistent significant hyperglycemia. At this level, symptoms of osmotic diuresis (polyuria, polydipsia), fatigue, blurred vision, and susceptibility to infection are expected.
Glycemic Target for This Patient
For a 73-year-old, the ADA-recommended target is not a one-size-fits-all figure:
- Cognitively intact, functionally independent, few comorbidities: HbA1c target <7.0–7.5% (same as younger adults)
- Multiple comorbidities, moderate functional limitations: HbA1c <8.0%
- Frail, limited life expectancy, significant comorbidities, dementia: HbA1c <8.5–9.0% (avoid hypoglycemia above all else)
"In an elderly individual with robust cognition and few major health issues, the glycemic goal may be the same as in younger individuals (HbA1c target <7.0%), while in an individual with impaired cognition or a resident of a long-term care facility, the goal may be less stringent (<8.0–8.5%) to minimize risk of hypoglycemia." — Harrison's Principles of Internal Medicine 22E
Given the magnitude of the gap (A1c 11.7% vs. target ~7.5–8%), this patient needs active intensification — not just lifestyle optimization.
Immediate Management Priorities
1. Assess Before You Prescribe
- Renal function (eGFR/creatinine) — critical for metformin and SGLT2 dosing
- Cardiovascular history — guides GLP-1 RA vs. SGLT2 choice
- Heart failure status — SGLT2 inhibitors have added benefit here
- Current medications and adherence — identify what's already been tried
- Symptoms of hyperglycemia — polyuria, polydipsia, weight loss, fatigue
- Risk of hypoglycemia — cognitive status, driving, living situation
2. Pharmacologic Intensification
With an A1c of 11.7%, combination therapy (or initiation of insulin) is generally warranted. The approach:
Step A — Metformin (if not already on it and eGFR ≥30)
- First-line for T2DM; weight-neutral, low hypoglycemia risk
- Start 500 mg with meals, titrate to 1000 mg BID
- Hold if eGFR <30; use caution if eGFR 30–45
Step B — Add a second agent with proven cardiorenal benefit
| Drug Class | Agent | Key Benefit | Caution in Elderly |
|---|---|---|---|
| GLP-1 RA | Semaglutide, liraglutide | CV protection, weight loss, A1c ↓1.5–2% | GI side effects; start low |
| SGLT2i | Empagliflozin, dapagliflozin | CV/renal protection, A1c ↓0.5–1% | UTI/genital infections; hold if eGFR <45 (dapa) or <20 (empa) |
| DPP-4i | Sitagliptin, linagliptin | Well-tolerated, low hypoglycemia | Less A1c reduction (~0.5–0.8%) |
For an A1c this far above goal, a GLP-1 RA is the strongest non-insulin option — semaglutide (oral or SC) can reduce A1c by up to 1.5–2.0%.
Step C — Consider Insulin if A1c >10–11% with symptoms
"Short-term (2 weeks to 3 months) intensive insulin treatment may be helpful when newly diagnosed individuals with type 2 diabetes have very elevated blood glucose." — Goldman-Cecil Medicine
- Options: Basal insulin (glargine or degludec once daily) — start at 10 units/night or 0.1–0.2 units/kg/day (~8–15 units)
- Titrate by 2 units every 3 days until fasting glucose is 80–130 mg/dL
- Degludec preferred in elderly for lower hypoglycemia risk
Estimated Dosing for Basal Insulin at 75 kg
- Starting dose: 0.1–0.2 units/kg/day = 8–15 units of glargine/degludec at bedtime
- Titrate upward based on fasting glucose readings
- Consider pairing with a GLP-1 RA (e.g., semaglutide) to minimize insulin requirements and assist with weight
Non-Pharmacologic Essentials
| Intervention | Goal |
|---|---|
| Medical nutrition therapy | Reduce carbohydrate load, consistent meal timing |
| Physical activity | 150 min/week moderate intensity if physically able |
| Diabetes self-management education | Blood glucose monitoring technique, hypoglycemia recognition |
| CGM consideration | Especially if starting insulin — improves time-in-range |
Monitoring Plan
- Repeat A1c in 3 months after therapy change
- Fasting glucose self-monitoring daily while titrating insulin
- eGFR, LFTs, urinalysis (microalbuminuria) — baseline and annually
- Blood pressure — target <130/80 in T2DM
- Lipids — statin therapy assessment (high CV risk in T2DM age >70)
- Annual foot exam, dilated eye exam, dental exam
Key Cautions in the Elderly
- Hypoglycemia is more dangerous at 73 — avoid sulfonylureas as first intensification step
- Dehydration risk with SGLT2i — ensure adequate fluid intake
- Weight loss with GLP-1 RA at 75 kg — monitor nutritional status
- Polypharmacy — review for drug interactions before adding agents
Sources: Harrison's Principles of Internal Medicine 22E; Goldman-Cecil Medicine; Katzung's Basic & Clinical Pharmacology 16E; Comprehensive Clinical Nephrology 7E
This is a shared conversation. Sign in to Orris to start your own chat.